Personalized medicine in psychiatry

被引:40
作者
Wium-Andersen, Ida Kim [1 ]
Vinberg, Maj [2 ]
Kessing, Lars Vedel [2 ]
McIntyre, Roger S. [3 ]
机构
[1] Psychiat Ctr Ballerup, Maglevaenget 2, DK-2750 Ballerup, Denmark
[2] Univ Copenhagen, Psychiat Ctr Copenhagen, Copenhagen, Denmark
[3] Univ Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
关键词
Biomarkers; diagnostic system; genetics; personalized medicine; psychiatry; RDoC; taxonomy; BIPOLAR DISORDER; CHILDHOOD ADVERSITIES; UNIPOLAR DEPRESSION; BRAIN MORPHOMETRY; SEX-DIFFERENCES; SCHIZOPHRENIA; METAANALYSIS; PHARMACOGENETICS; BIOMARKERS; TESTOSTERONE;
D O I
10.1080/08039488.2016.1216163
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Personalized medicine is a model in which a patient's unique clinical, genetic, and environmental characteristics are the basis for treatment and prevention.Aim, method, and results: This review aims to describe the current tools, phenomenological features, clinical risk factors, and biomarkers used to provide personalized medicine. Furthermore, this study describes the target areas in which they can be applied including diagnostics, treatment selection and response, assessment of risk of side-effects, and prevention.Discussion and conclusion: Personalized medicine in psychiatry is challenged by the current taxonomy, where the diagnostic categories are broad and great biological heterogeneity exists within each category. There is, thus, a gap between the current advanced research prospects and clinical practice, and the current taxonomy is, thus, a poor basis for biological research. The discussion proposes possible solutions to narrow this gap and to move psychiatric research forward towards personalized medicine.
引用
收藏
页码:12 / 19
页数:8
相关论文
共 107 条
  • [1] Aboraya Ahmed, 2005, Psychiatry (Edgmont), V2, P48
  • [2] [Anonymous], 2006, DEMENTIA SUPPORTING
  • [3] [Anonymous], RES DOM CRIT
  • [4] Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis
    Arnone, D.
    Cavanagh, J.
    Gerber, D.
    Lawrie, S. M.
    Ebmeier, K. P.
    McIntosh, A. M.
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2009, 195 (03) : 194 - 201
  • [5] Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
    Arranz, M. J.
    de Leon, J.
    [J]. MOLECULAR PSYCHIATRY, 2007, 12 (08) : 707 - 747
  • [6] The schizophrenia phenotype in 22q11 deletion syndrome
    Bassett, AS
    Chow, EWC
    AbdelMalik, P
    Gheorghiu, M
    Husted, J
    Weksberg, R
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (09) : 1580 - 1586
  • [7] Anxiety disorders: Sex differences in prevalence, degree, and background, but gender-neutral treatment
    Bekker, Marrie H. J.
    van Mens-Verhulst, Janneke
    [J]. GENDER MEDICINE, 2007, 4 : S178 - S193
  • [8] Volumetric brain imaging findings in mood disorders
    Beyer, JL
    Krishnan, KRR
    [J]. BIPOLAR DISORDERS, 2002, 4 (02) : 89 - 104
  • [9] Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
    Buchhave, Peder
    Minthon, Lennart
    Zetterberg, Henrik
    Wallin, Asa K.
    Blennow, Kaj
    Hansson, Oskar
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2012, 69 (01) : 98 - 106
  • [10] Clinical science and biomarkers: against RDoC
    Carroll, B. J.
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2015, 132 (06) : 423 - 424